MTAC

Avilar Therapeutics to Present Preclinical Data for MTAC (M6PR Targeting Chimera) Extracellular Protein Degrader Platform at the American Association of Immunologists Annual Meeting

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Pharmaceutical, Health, MTAC, M6P, ATAC, Protein, Hepatocyte, Ligand, Publication, Poster, Doctor of Philosophy, Journal, Chimera, ATACS, Therapy, Asialoglycoprotein receptor, Atomic mass, Fine chemical

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company’s MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company’s MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois.
  • MTACs are novel bifunctional molecules containing a proprietary Avilar ligand to the mannose 6‑phosphate receptor (M6PR) conjugated to a second ligand that binds to a protein of interest for degradation.
  • MTACs represent an expansion of Avilar’s capabilities for extracellular protein degradation, building on the company’s ATAC (ASGPR Targeting Chimera) platform, which utilizes the asialoglycoprotein receptor (ASGPR) for degradation of proteins in the hepatocyte endolysosome.
  • Avilar scientists invented novel high affinity ligands to both ASGPR and M6PR, and these ligands form the chemistry backbone for ATACs and MTACs, respectively.

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Retrieved on: 
Monday, February 26, 2024
SAN, Metabolism, Inflammation, Food, HDAC6, HDAC, Exercise, Tubulin, Heart failure, Safety, Therapy, Acetylation, Patient, Hypertrophy, Fibrosis, SGLT2, MTAC, Oxidative stress, Nature Communications, Heart, HFD, Plasma, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6), including TN-301, in the February 26, 2024, issue of Nature Communications. The article, titled “Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice,” details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction (HFpEF), a form of heart failure that effects more than three million people in the U.S. alone1.

Key Points: 
  • The article, titled “Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice,” details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction (HFpEF), a form of heart failure that effects more than three million people in the U.S. alone1.
  • Tenaya’s highly selective small molecule inhibitors of the enzyme HDAC6 were discovered using the company’s modality-agnostic target discovery and validation capabilities.
  • For preclinical studies, Tenaya researchers used TYA-018, an HDAC6 inhibitor structurally and functionally similar to the company’s clinical candidate, TN-301.
  • The selective effects of HDAC6 inhibition were reaffirmed through genetic deletion studies, in which treatment of Hdac6 knockout mice did not display any of the beneficial effects that wild-type HFpEF mice did following treatment.

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

Retrieved on: 
Thursday, August 10, 2023
Health, Oncology, Clinical Trials, Well, LLP, Drug, Therapy, Liver disease, Myeloid-derived suppressor cell, Hepatocellular carcinoma, Neoplasm, Clinical trial, Pancreas, MDSC, Hope, Uveal melanoma, Cancer, MTAC, Toxicity, Foley & Lardner, Cholangiocarcinoma, Immunotherapy, JJ, ASCO, Cooley LLP, Patient, Blood, Liver, Growth, TLR, FDA, Hand, Environment, Medtech, MD Anderson Cancer Center, Tumor microenvironment, Pharmaceutical industry, Medical imaging

TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech).

Key Points: 
  • TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech).
  • “Completing our merger with MedTech marks an important milestone in our efforts to bring to market innovative approaches to treating liver and pancreatic tumors,” said Mary Szela, President and CEO of TriSalus.
  • Finally, I want to especially thank our MTAC and TriSalus shareholders for trusting us to create value for them.
  • Robust Device Pipeline: TriSalus' technology pipeline includes a range of devices that use technology expected to substantially improve therapeutic delivery.

MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

Retrieved on: 
Wednesday, August 2, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Transfer, Shareholder, MTAC, Special, Form, Webcast, FDA, Holding company

MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeting”).

Key Points: 
  • MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeting”).
  • The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the “Business Combination”) with TriSalus Life Sciences (“TriSalus”).
  • The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023.
  • The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023 .

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 12, 2023
Oncology, Medical Devices, Health, Research, Science, Biotechnology, Drug, CT, Interferon gamma, Liver disease, Serum, American Society of Clinical Oncology, Business, Immunotherapy, Uveal melanoma, MTAC, Cell, Trial of the century, ASCO, MDSC, Patient, Mass, Blood, Annual general meeting, Mass General Brigham, FACS, Liver, Neoplasm, Therapy, Society, Medtech, Medical imaging, Vaccine, Pharmaceutical industry, MD

PERIO-01 is evaluating whether this platform approach can improve the performance of systemic checkpoint inhibitors in patients with UMLM.

Key Points: 
  • PERIO-01 is evaluating whether this platform approach can improve the performance of systemic checkpoint inhibitors in patients with UMLM.
  • PERIO-01 is an open-label, first-in-human Phase 1 trial of SD-101, administered by hepatic arterial infusion with TriNav using PEDD in UMLM.
  • The study consists of dose-escalation cohorts of SD-101 (2, 4, or 8 mg) alone or with immune checkpoint inhibition.
  • The data were also selected for presentation at the Developmental Therapeutics - Immunotherapy Poster Discussion Session on June 3, 2023 at 3:00pm CT.

Nile Hardens Enterprise Network(aaS) With Integrated Security Defenses

Retrieved on: 
Wednesday, March 29, 2023
IEEE 802.1AE, Internet of things, SDI, Hope, Network as a service, MTAC, Organization, SAN, Communication, Sigma, Avaya Unified Communications Management, Mobile phone

SAN JOSE, Calif., March 29, 2023 /PRNewswire/ -- Nile, a leader in enterprise network as a service, today announced a series of new security capabilities designed to protect against threats that have long plagued wired and wireless networks. Based on the principles of zero trust, Nile's secure-by-design approach removes the complexities that have exponentially increased the cost and effort required to secure users and devices against advanced threats. Threats are designed to take advantage of gaps in an organization's security posture that allow attackers to easily gain access to their network, discover other devices, and move silently across the network to achieve their ultimate objective.

Key Points: 
  • The drive towards enterprise network as a service (NaaS) is fueled in part by a desire to make networks more secure.
  • "The network industry has imposed an immense burden on organizations, often forcing teams into uneasy compromises," said Suresh Katukam, co-founder, and chief product officer at Nile.
  • Every user and device, human or IoT, is authenticated and authorized before providing any access to the Nile network.
  • Eliminates malware proliferation by isolating every user and device from all other users and devices on the Nile network.

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

Retrieved on: 
Monday, November 21, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Communication, Clinical trial, Environment, Proxy, Drug, Acquisition, Mergers and acquisitions, Person, Maple Avenue/Maple Lane Historic District, Growth, Register, Risk, Name, Immunotherapy, Blood, Section 10 of the Canadian Charter of Rights and Freedoms, Liver tumor, Liver, XV, Form, Prospectus, 100,000, Neoplasm, TLR9, FACS, MTAC, Business, Form S-1, Tripura Merger Agreement, FDA, Sale, Business architecture, Registration statement, Pressure, XXV, Failure, CRIMINAL, Annual report, Therapy, Special, MDSC, Medtech, Myeloid-derived suppressor cell, Patient, Medical imaging, Pharmaceutical industry, Risk management, Security (finance), MD

The initial findings from these studies offer encouraging data supporting TriSalus proprietary Pressure-Enabled Drug Delivery (PEDD) method, said Steven C. Katz, MD, FACS, Chief Medical Officer at TriSalus.

Key Points: 
  • The initial findings from these studies offer encouraging data supporting TriSalus proprietary Pressure-Enabled Drug Delivery (PEDD) method, said Steven C. Katz, MD, FACS, Chief Medical Officer at TriSalus.
  • The Company expects PERIO 01 and PERIO 02 Phase 1 response data in December 2022.
  • The studies continue to enroll at higher SD-101 dose levels in combination with checkpoint inhibitors.
  • TriSalus is an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors.

IWCO Direct's Director of Postal Affairs Elected as New MTAC Industry Vice Chair

Retrieved on: 
Wednesday, September 18, 2019
Business economics, Market economics), Microeconomics, MTAC, Chanhassen, Minnesota, Marketing, Rosser, Direct marketing

Chanhassen, Minn., Sept. 18, 2019 /PRNewswire-PRWeb/ --IWCO Direct, a leading provider of data-driven direct marketing solutions, announced Bob Rosser, its Director of Postal Affairs, has been appointed Industry Vice Chair of the Postmaster General's Mailers' Technical Advisory Committee (MTAC).

Key Points: 
  • Chanhassen, Minn., Sept. 18, 2019 /PRNewswire-PRWeb/ --IWCO Direct, a leading provider of data-driven direct marketing solutions, announced Bob Rosser, its Director of Postal Affairs, has been appointed Industry Vice Chair of the Postmaster General's Mailers' Technical Advisory Committee (MTAC).
  • Rosser was elected to the position at a recent MTAC meeting and will serve in the role through the end of 2020, when he will become MTAC Industry Chair through the end of 2023.
  • MTAC works for the mutual benefit of mailing industry stakeholders and the Postal Service to enhance customer value and expand the use of these products and services.
  • Stay current on direct marketing trends, industry news, postal regulations, and more by subscribing to IWCO Direct's SpeakingDIRECT blog.